Mauna Kea's Microscopy System Found Effective in Cancer Detection
Posted on: Monday, 19 May 2008, 12:00 CDT
Mauna Kea Technologies has reported positive results from a new study which showed that its Cellvizio confocal microscopy improves ERCP bile duct cancer detection.
The 14-patient clinical trial evaluated the ability of Mauna Kea Technology's Cellvizio confocal microscopy system to detect cancer in biliary tract tissue by examining tissue at the cellular level during endoscopic retrograde cholangiopancreatography (ERCP), a procedure used to diagnose cancer of the bile ducts and pancreas.
The study found that Cellvizio predicted cancer with an accuracy rate of 91.7%, which was superior to the 76.9% accuracy rate of histopathological analysis of biopsied tissue taken from strictures. Usually, the preoperative diagnosis of cancer of the bile ducts, medically known as cholangiocarcinoma, is associated with a low accuracy rate.
Alexander Meining, managing director of the Technical University of Munich, said: "This new tool could be of utmost importance as cholangiocarcinoma remains one of the cancers with the poorest prognosis. We believe the potential for improved accuracy of diagnosis is due to the real- time, cellular-level images the technology provides on benign and malignant biliaro-pancreatic strictures."
Source: Datamonitor
Related Articles
- Pancreatic Cancer Affects Blacks at Higher Rate
- Research Finds New Pathology Tests Double Sensitivity To Detect Bile Duct And Pancreatic Cancers
- Lithium Could Help Radiation Target Cancer, Spare Healthy Tissue
- Optimal Boost Approach to Breast Cancer Treatment Significantly Reduces Recurrence Rate and Increases Survival Rate
- Most Cancers Do Not Increase Divorce Rate
- Gsk's Pazopanib Shows Positive Results in Patients With Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
- Cancer Tied to Race, Screening Rates: STUDY MAY EXPLAIN WHY BLACKS HAVE MORE CASES OF ADVANCED BREAST CANCER
- Early Prostate Cancer Screening May Reduce Mortality Rate
- ADVENTRX Reports Positive Preliminary Phase II Trial Results With CoFactor in Metastatic Colorectal Cancer; Data Show Increased Response Rate and No Grade 3/4 Gastrointestinal or Hematological Toxicity
- Skin Cancer Growing at an Alarming Rate
 |
 |
User Comments (0)
RSS Feeds